Company / R&D Expense
Cytokinetics R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$416.0M
FY2025
5-year range
$159.9M / $416.0M
FY2021-FY2025
Trend
+22.6%
vs FY2024
Sector context
#42 of 210
Health Care
What the data says
Cytokinetics's r&d expense of $416M is higher than 80% of companies in the Health Care sector (FY2025). R&D Expense has increased for 6 consecutive years, from $86M in FY2019 to $416M in FY2025.
Based on SEC 10-K filings.
$416M in FY2025 with a 5-year CAGR of +33.8%. Top quartile in the Health Care sector.
Improved from $330M to $416M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +20.0%
- 5-Year CAGR
- +33.8%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 210This company $416.0M Sector average $644.1M
▼
-35.4% below sector average
Key checks
Key Insights
- Cytokinetics's r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +33.8%, indicating consistent growth.
- In FY2025, r&d expense increased 22.6% year-over-year.
- Ranks #42 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $416.0M | +22.6% |
| FY2024 | $339.4M | +2.8% |
| FY2023 | $330.1M | +37.1% |
| FY2022 | $240.8M | +50.6% |
| FY2021 | $159.9M | +65.0% |
| FY2020 | $97.0M | +12.6% |
| FY2019 | $86.1M | -3.4% |
| FY2018 | $89.1M | -1.3% |
| FY2017 | $90.3M | +50.8% |
| FY2016 | $59.9M | +29.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026